JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic and immunotherapeutic potential of disulfidptosis-associated signature in pancreatic cancer

  • 0Department of Hepatopancreatobiliary Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Frontiers in Immunology +

|

April 10, 2025

|

April 10, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Disulfidptosis, a programmed cell death, plays a key role in pancreatic ductal adenocarcinoma. This study developed an 8-gene signature to predict prognosis and immune checkpoint blockade sensitivity in PDAC patients.

Area Of Science

  • Oncology
  • Cell Biology
  • Bioinformatics

Background

  • Disulfidptosis is a newly identified programmed cell death mechanism.
  • The role of disulfidptosis in pancreatic ductal adenocarcinoma (PDAC) is not well understood.

Purpose Of The Study

  • To investigate the significance of disulfidptosis in PDAC.
  • To develop a prognostic signature for PDAC based on disulfidptosis-related genes.

Main Methods

  • Integrated multi-omics data (bulk RNA-seq, microarray, single-cell, spatial transcriptomics) and biospecimens.
  • Screened and validated disulfidptosis-related genes using bioinformatics.
  • Constructed and validated an 8-gene prognostic signature (DPS) using LASSO-Cox regression and external PDAC cohorts.

Main Results

  • An 8-gene disulfidptosis-related prognostic signature (DPS) was established and validated.
  • High DPS scores correlated with poorer prognosis and reduced sensitivity to immune checkpoint blockade.
  • Elevated DPS was linked to tumor hallmarks, myCAF-tumor cell interactions, and immune cell exclusion.

Conclusions

  • A novel, highly effective disulfidptosis-related signature aids in PDAC patient risk stratification.
  • The signature can predict sensitivity to immune checkpoint blockade therapy.
  • MyCAF-tumor cell crosstalk, mediated by signaling networks, contributes to PDAC malignancy.

Keywords: